Asia Pacific Preventive Vaccines Market
Asia Pacific preventive vaccines market will grow by 13.32% annually with a total addressable mar ... Read More
1 Introduction 7 1.1 Industry Definition and Research Scope 7 1.1.1 Industry Definition 7 1.1.2 Research Scope 8 1.2 Research Methodology 11 1.2.1 Overview of Market Research Methodology 11 1.2.2 Market Assumption 12 1.2.3 Secondary Data 12 1.2.4 Primary Data 12 1.2.5 Data Filtration and Model Design 13 1.2.6 Market Size/Share Estimation 14 1.2.7 Research Limitations 15 1.3 Executive Summary 16 2 Market Overview and Dynamics 19 2.1 Market Size and Forecast 19 2.1.1 Impact of COVID-19 on World Economy 21 2.1.2 Impact of COVID-19 on the Market 23 2.2 Major Growth Drivers 25 2.3 Market Restraints and Challenges 28 2.4 Emerging Opportunities and Market Trends 31 2.5 Porter’s Fiver Forces Analysis 35 3 Segmentation of Europe Market by Vaccine Type 39 3.1 Market Overview by Vaccine Type 39 3.2 Live/Attenuated Vaccines 41 3.3 Inactivated Vaccines 42 3.4 Subunit Vaccines 43 3.5 Toxoid Vaccines 44 3.6 Conjugate Vaccines 45 3.7 Recombinant Vector Vaccines 46 3.8 Other Vaccines 47 4 Segmentation of Europe Market by Disease 48 4.1 Market Overview by Disease 48 4.2 Vaccines for Pneumococcal Disease 50 4.3 Vaccines for Poliovirus 51 4.4 Vaccines for Hepatitis 52 4.5 Vaccines for Influenza 53 4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 54 4.7 Vaccines for Varicella 55 4.8 Vaccines for Human Papilloma Virus 56 4.9 Vaccines for COVID-19 57 4.10 Vaccines for Other Diseases 60 5 Segmentation of Europe Market by Administration 61 5.1 Market Overview by Administration 61 5.2 Intramuscular Route 63 5.3 Subcutaneous Route 64 5.4 Oral Route 65 5.5 Intravenous Injection 66 5.6 Other Administration Routes 67 6 Segmentation of Europe Market by Patient 68 6.1 Market Overview by Patient 68 6.2 Pediatric Vaccines 70 6.3 Adult Vaccines 72 7 European Market 2020-2026 by Country 74 7.1 Overview of European Market 74 7.2 UK 77 7.3 France 80 7.4 Germany 83 7.5 Spain 86 7.6 Italy 89 7.7 Russia 92 7.8 Rest of European Market 95 8 Competitive Landscape 97 8.1 Overview of Key Vendors 97 8.2 New Product Launch, Partnership, Investment, and M&A 100 8.3 Company Profiles 101 AstraZeneca plc 101 Bavarian Nordic A/S 104 China National Biotec Group Company Ltd. 107 CSL Ltd. 109 Daiichi Sankyo Co. Ltd 111 Emergent BioSolutions Inc. 113 GlaxoSmithKline plc 115 Johnson & Johnson 119 Merck & Co. 121 Moderna Inc. 123 Novavax, Inc. 124 Pfizer Inc. 126 Sanofi SA 130 Takeda Pharmaceutical Co. Ltd. 132 9 Investing in Europe Market: Risk Assessment and Management 134 9.1 Risk Evaluation of Europe Market 134 9.2 Critical Success Factors (CSFs) 137 Related Reports and Products 140
Table 1. Snapshot of Europe Preventive Vaccines Market in Balanced Perspective, 2020-2026 17 Table 2. Growth Rate of World GDP, 2020-2022 22 Table 3. Main Product Trends and Market Opportunities in Europe Preventive Vaccines Market 31 Table 4. Europe Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 39 Table 5. Europe Preventive Vaccines Market by Disease, 2016-2026, $ mn 48 Table 6. COVID-19 Vaccines Authorized for Emergency Use or Approved for Full Use, as of April 2021 58 Table 7. Europe Preventive Vaccines Market by Administration, 2016-2026, $ mn 61 Table 8. Europe Preventive Vaccines Market by Patient, 2016-2026, $ mn 68 Table 9. Europe Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn 71 Table 10. Europe Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn 73 Table 11. Europe Preventive Vaccines Market by Country, 2016-2026, $ mn 76 Table 12. UK Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 78 Table 13. UK Preventive Vaccines Market by Disease, 2016-2026, $ mn 78 Table 14. UK Preventive Vaccines Market by Administration, 2016-2026, $ mn 79 Table 15. France Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 81 Table 16. France Preventive Vaccines Market by Disease, 2016-2026, $ mn 81 Table 17. France Preventive Vaccines Market by Administration, 2016-2026, $ mn 82 Table 18. Germany Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 84 Table 19. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn 84 Table 20. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn 85 Table 21. Spain Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 87 Table 22. Spain Preventive Vaccines Market by Disease, 2016-2026, $ mn 87 Table 23. Spain Preventive Vaccines Market by Administration, 2016-2026, $ mn 88 Table 24. Italy Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 90 Table 25. Italy Preventive Vaccines Market by Disease, 2016-2026, $ mn 90 Table 26. Italy Preventive Vaccines Market by Administration, 2016-2026, $ mn 91 Table 27. Russia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 93 Table 28. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn 93 Table 29. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn 94 Table 30. Preventive Vaccines Market in Rest of Europe by Country, 2016-2026, $ mn 96 Table 31. AstraZeneca plc: Company Snapshot 101 Table 32. AstraZeneca plc: Revenue, 2018-2020, $ bn 102 Table 33. Bavarian Nordic A/S: Company Snapshot 104 Table 34. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020 105 Table 35. China National Biotec Group Company Ltd.: Company Snapshot 107 Table 36. CSL Ltd.: Company Snapshot 109 Table 37. Daiichi Sankyo Co. Ltd.: Company Snapshot 111 Table 38. Emergent BioSolutions Inc.: Company Snapshot 113 Table 39. GlaxoSmithKline: Company Snapshot 115 Table 40. GlaxoSmithKline: Business Segmentation 116 Table 41. GlaxoSmithKline: Product Portfolio 117 Table 42. GlaxoSmithKline: Revenue, 2018-2020, $ bn 118 Table 43. GlaxoSmithKline: Recent Developments 118 Table 44. Johnson & Johnson: Company Snapshot 119 Table 45. Johnson & Johnson: Business Segments 120 Table 46. Merck & Co., Inc.: Company Snapshot 121 Table 47. Merck & Co., Inc.: Business Segmentation 121 Table 48. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 122 Table 49. Moderna Inc.: Company Snapshot 123 Table 50. Novavax, Inc.: Company Snapshot 124 Table 51. Pfizer Inc.: Company Snapshot 126 Table 52. Pfizer Inc.: Business Segmentation 127 Table 53. Pfizer Inc.: Product Portfolio 128 Table 54. Pfizer Inc.: Revenue, 2018-2020, $ bn 129 Table 55. Pfizer Inc.: Recent Developments 129 Table 56. Sanofi: Company Snapshot 130 Table 57. Sanofi: Business Segmentation 130 Table 58. Sanofi: Revenue, 2018-2020, $ bn 131 Table 59. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 132 Table 60. Risk Evaluation for Investing in Europe Market, 2020-2026 135 Table 61. Critical Success Factors and Key Takeaways 138
Figure 1. Research Method Flow Chart 11 Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14 Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2026 16 Figure 4. Europe Preventive Vaccines Market, 2016-2026, $ mn 19 Figure 5. Development Stages of Preventive Vaccines 20 Figure 6. Impact of COVID-19 on Business 23 Figure 7. Primary Drivers and Impact Factors of Europe Preventive Vaccines Market 25 Figure 8. Primary Restraints and Impact Factors of Europe Preventive Vaccines Market 28 Figure 9. Investment Opportunity Analysis 32 Figure 10. Porter’s Fiver Forces Analysis of Europe Preventive Vaccines Market 35 Figure 11. Breakdown of Europe Preventive Vaccines Market by Vaccine Type, 2020-2026, % of Revenue 40 Figure 12. Contribution to Europe 2021-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%) 40 Figure 13. Europe Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn 41 Figure 14. Europe Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn 42 Figure 15. Europe Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn 43 Figure 16. Europe Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn 44 Figure 17. Europe Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn 45 Figure 18. Europe Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn 46 Figure 19. Europe Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn 47 Figure 20. Breakdown of Europe Preventive Vaccines Market by Disease, 2020-2026, % of Revenue 49 Figure 21. Contribution to Europe 2021-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%) 49 Figure 22. Europe Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn 50 Figure 23. Europe Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn 51 Figure 24. Europe Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn 52 Figure 25. Europe Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn 53 Figure 26. Europe Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn 54 Figure 27. Europe Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn 55 Figure 28. Europe Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn 56 Figure 29. Europe Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn 57 Figure 30. Europe Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn 60 Figure 31. Breakdown of Europe Preventive Vaccines Market by Administration, 2020-2026, % of Revenue 62 Figure 32. Contribution to Europe 2021-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%) 62 Figure 33. Europe Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn 63 Figure 34. Europe Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn 64 Figure 35. Europe Preventive Vaccines Market: Oral Route, 2016-2026, $ mn 65 Figure 36. Europe Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn 66 Figure 37. Europe Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn 67 Figure 38. Breakdown of Europe Preventive Vaccines Market by Patient, 2020-2026, % of Revenue 68 Figure 39. Contribution to Europe 2021-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%) 69 Figure 40. Europe Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn 70 Figure 41. Europe Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn 72 Figure 42. Breakdown of European Preventive Vaccines Market by Country, 2020 and 2026, % of Revenue 75 Figure 43. Contribution to Europe 2021-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 76 Figure 44. Preventive Vaccines Market in UK, 2016-2026, $ mn 77 Figure 45. Preventive Vaccines Market in France, 2016-2026, $ mn 80 Figure 46. Preventive Vaccines Market in Germany, 2016-2026, $ mn 83 Figure 47. Preventive Vaccines Market in Spain, 2016-2026, $ mn 86 Figure 48. Preventive Vaccines Market in Italy, 2016-2026, $ mn 89 Figure 49. Preventive Vaccines Market in Russia, 2016-2026, $ mn 92 Figure 50. Preventive Vaccines Market in Rest of Europe, 2016-2026, $ mn 95 Figure 51. Growth Stage of Europe Preventive Vaccines Industry over the Forecast Period 97 Figure 52. Top Products of AstraZeneca Based on Revenue from 2016 to 2019 (in million U.S. dollars) 102
Key Players (this may not be a complete list and extra companies can be added upon request): AstraZeneca plc Bavarian Nordic A/S China National Biotec Group Company Ltd. CSL Ltd. Daiichi Sankyo Co. Ltd Emergent BioSolutions Inc. GlaxoSmithKline plc Johnson & Johnson Merck & Co. Moderna Inc. Novavax, Inc. Pfizer Inc. Sanofi SA Takeda Pharmaceutical Co. Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Asia Pacific preventive vaccines market will grow by 13.32% annually with a total addressable mar ... Read More
Global virus filtration market will reach $6,275.3 million by 2026, growing by 12.26% annually ov ... Read More
North America virus filtration market is expected to grow by 11.86% annually in the forecast peri ... Read More
Europe virus filtration market accounted for $696.7 million in 2019 and will grow by 11.34% annua ... Read More